HCPLive

Increased QRS Duration on ECG Tied to Cardiovascular Mortality

 
THURSDAY, Sept. 19 (HealthDay News) -- Increased QRS duration on electrocardiogram (ECG) is an independent predictor of cardiovascular mortality, according to a study published in the Sept. 1 issue of The American Journal of Cardiology.

Apurva Omkar Badheka, M.D., from the University of Miami, and colleagues retrospectively reviewed prospectively collected data from the National Health and Nutrition Examination Survey data set to identify 8,527 patients (mean age, 60.5 years; 87 percent white; 53 percent women) with ECG data available.

The researchers found that over 106,244.6 person-years of follow-up there were 1,433 cardiovascular deaths. After adjusting for established risk factors, the highest quartile of QRS duration was associated with significantly higher cardiovascular mortality than the lowest quartile (hazard ratio [HR], 1.3). There was also a significant association between both left bundle branch block (BBB; HR, 2.4) and right BBB (HR, 1.90) and increased cardiovascular mortality. There was an overall net reclassification improvement of 4.4 percent with the addition of the QRS duration in 10-millisecond increments to the Framingham Risk Score model.

"A model including QRS duration in addition to traditional risk factors was associated with improved cardiovascular risk prediction," the authors write.

Abstract 

Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.
 
 
 

Most Popular

Recommended Reading

Medications in general can take a long time to develop. Depending on the condition they treat that process can be even longer as more questions have to be answered before they can be introduced to the field. This is particularly true of multiple sclerosis treatments.
As a treatment for multiple sclerosis teriflunomide has shown benefits over a long development period and has proven effective in the treatment of patients with the relapsing-remitting form of the condition.
For as many drugs and therapies as there are for multiple sclerosis some are more aggressive than others. Alemtuzumab's approach is more on the aggressive end of the spectrum.
During a time when antibiotic resistance concerns are at an all-time high, a Texas-based team called for backup in the fight against pneumonia.
$vAR$